Your browser doesn't support javascript.
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.
Adetifa, Ifedayo M O; Uyoga, Sophie; Gitonga, John N; Mugo, Daisy; Otiende, Mark; Nyagwange, James; Karanja, Henry K; Tuju, James; Wanjiku, Perpetual; Aman, Rashid; Mwangangi, Mercy; Amoth, Patrick; Kasera, Kadondi; Ng'ang'a, Wangari; Rombo, Charles; Yegon, Christine; Kithi, Khamisi; Odhiambo, Elizabeth; Rotich, Thomas; Orgut, Irene; Kihara, Sammy; Bottomley, Christian; Kagucia, Eunice W; Gallagher, Katherine E; Etyang, Anthony; Voller, Shirine; Lambe, Teresa; Wright, Daniel; Barasa, Edwine; Tsofa, Benjamin; Bejon, Philip; Ochola-Oyier, Lynette I; Agweyu, Ambrose; Scott, J Anthony G; Warimwe, George M.
  • Adetifa IMO; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. IAdetifa@kemri-wellcome.org.
  • Uyoga S; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom. IAdetifa@kemri-wellcome.org.
  • Gitonga JN; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. SUyoga@kemri-wellcome.org.
  • Mugo D; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Otiende M; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Nyagwange J; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Karanja HK; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Tuju J; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Wanjiku P; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Aman R; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Mwangangi M; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Amoth P; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Kasera K; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Ng'ang'a W; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Rombo C; Presidential Policy & Strategy Unit, The Presidency, Government of Kenya, Nairobi, Kenya.
  • Yegon C; Kenya National Blood Transfusion Services, Ministry of Health, Nairobi, Kenya.
  • Kithi K; Kenya National Blood Transfusion Services, Ministry of Health, Nairobi, Kenya.
  • Odhiambo E; Kenya National Blood Transfusion Services, Ministry of Health, Nairobi, Kenya.
  • Rotich T; Kenya National Blood Transfusion Services, Ministry of Health, Nairobi, Kenya.
  • Orgut I; Kenya National Blood Transfusion Services, Ministry of Health, Nairobi, Kenya.
  • Kihara S; Kenya National Blood Transfusion Services, Ministry of Health, Nairobi, Kenya.
  • Bottomley C; Kenya National Blood Transfusion Services, Ministry of Health, Nairobi, Kenya.
  • Kagucia EW; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom.
  • Gallagher KE; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Etyang A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Voller S; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom.
  • Lambe T; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Wright D; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Barasa E; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom.
  • Tsofa B; Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
  • Bejon P; Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
  • Ochola-Oyier LI; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Agweyu A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Scott JAG; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Warimwe GM; Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
Nat Commun ; 12(1): 3966, 2021 06 25.
Article in English | MEDLINE | ID: covidwho-1281718
ABSTRACT
Observed SARS-CoV-2 infections and deaths are low in tropical Africa raising questions about the extent of transmission. We measured SARS-CoV-2 IgG by ELISA in 9,922 blood donors across Kenya and adjusted for sampling bias and test performance. By 1st September 2020, 577 COVID-19 deaths were observed nationwide and seroprevalence was 9.1% (95%CI 7.6-10.8%). Seroprevalence in Nairobi was 22.7% (18.0-27.7%). Although most people remained susceptible, SARS-CoV-2 had spread widely in Kenya with apparently low associated mortality.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Africa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24062-3

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Africa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24062-3